Maratia (Tramadol Hydrochloride, Paracetamol)

Tramadol Hydrochloride binds to μ‑opioid receptors, producing opioid‑like analgesia, and simultaneously inhibits the reuptake of norepinephrine and serotonin, enhancing descending pain‑modulating pathways. This dual action contributes to its effectiveness in acute pain states.

The appropriate dose of Maratia is determined by the prescribing clinician based on the patient’s pain severity, medical history, and concurrent therapies. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidance.

Safety data for Maratia in pregnancy and lactation are limited. Tramadol crosses the placenta and may cause neonatal withdrawal, while paracetamol is generally considered low risk. Clinicians should weigh potential benefits against risks before prescribing to pregnant or nursing women.

To order Maratia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑agent tramadol, Maratia adds paracetamol, which can enhance analgesia while allowing lower opioid doses. Relative to pure paracetamol, the combination offers stronger relief for moderate‑to‑severe pain but carries additional opioid‑related risks that require careful monitoring.

Maratia should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight or excessive humidity.

Maratia is taken orally, usually with a full glass of water. It may be taken with or without food, but a consistent approach (with meals or on an empty stomach) can help minimize gastrointestinal discomfort.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience difficulty breathing, severe rash, or unexplained swelling.

Maratia is contraindicated in individuals with known hypersensitivity to tramadol, paracetamol, or any component of the formulation, as well as in patients who have taken monoamine‑oxidase inhibitors within the past 14 days. Caution is also advised for those with severe respiratory disorders or uncontrolled epilepsy.